Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of HUMIRA (Adalimumab sc) for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice

Trial Profile

Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of HUMIRA (Adalimumab sc) for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LOTOS
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Oct 2020 to 1 Jan 2021.
    • 30 Jan 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.
    • 01 Aug 2016 Planned number of patients changed from 5500 to 3000.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top